BioLineRx (BLRX) Free Cash Flow Growth (3y) (2016 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 24.91% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.71% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -10.65% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 31.42% |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | 17.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.15% |
| Sep 30, 2025 | 37.61% |
| Jun 30, 2025 | 69.51% |
| Mar 31, 2025 | 22.51% |
| Dec 31, 2024 | -16.56% |
| Sep 30, 2024 | -25.12% |
| Jun 30, 2024 | -18.40% |
| Mar 31, 2024 | -31.36% |
| Dec 31, 2023 | 42.96% |
| Sep 30, 2023 | -21.86% |
| Jun 30, 2023 | -19.99% |
| Mar 31, 2023 | -5.82% |
| Dec 31, 2022 | -1.27% |
| Sep 30, 2022 | -12.02% |
| Jun 30, 2022 | 0.93% |
| Mar 31, 2022 | -6.64% |
| Dec 31, 2021 | -2.56% |
| Sep 30, 2021 | 5.85% |
| Jun 30, 2021 | -3.11% |
| Mar 31, 2021 | 2.76% |
| Dec 31, 2020 | 3.76% |
| Sep 30, 2020 | 4.07% |
| Jun 30, 2020 | -10.11% |
| Mar 31, 2020 | -21.59% |
| Dec 31, 2019 | -8.88% |
| Sep 30, 2019 | -27.41% |
| Jun 30, 2019 | -25.69% |
| Mar 31, 2019 | -4.29% |
| Dec 31, 2018 | -19.30% |
| Sep 30, 2018 | -26.71% |
| Jun 30, 2018 | -40.49% |
| Mar 31, 2018 | -26.72% |
| Dec 31, 2017 | -8.73% |
| Sep 30, 2017 | -24.97% |
| Jun 30, 2017 | 1.04% |
| Mar 31, 2017 | -3.88% |
| Dec 31, 2016 | -4.41% |
| Sep 30, 2016 | 11.53% |
| Jun 30, 2016 | 19.48% |
| Mar 31, 2016 | 8.30% |